Panoprist (Perindopril Tert-Butylamine, Indapamide)

Perindopril arginine, the active ingredient in Panoprist, is an ACE‑inhibitor presented as a tablet for oral use. It treats hypertension and related cardiovascular conditions in adult patients.

GNH USA supplies Panoprist as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Panoprist is used in the management of cardiovascular disorders that involve the renin‑angiotensin system. - Hypertension: lowers systolic and diastolic blood pressure to reduce stroke risk. - Chronic heart failure: improves ventricular function and decreases hospitalisation rates. - Post‑myocardial infarction: helps prevent adverse cardiac remodeling and further events.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness: especially when standing quickly. - Headache: mild to moderate intensity. - Fatigue: general sense of tiredness. - Hyperkalemia: elevated blood potassium levels. - Renal function changes: rise in serum creatinine.

Serious or Rare Side Effects: - Angioedema: swelling of lips, tongue or airway. - Severe hypotension: marked drop in blood pressure. - Acute kidney injury: rapid decline in renal function. - Neutropenia: low white‑blood‑cell count. - Hepatotoxicity: abnormal liver enzymes. - Anaphylaxis: life‑threatening allergic reaction.

Before prescribing Panoprist, clinicians should evaluate patient history and monitor relevant parameters. - Renal impairment: adjust dose and monitor creatinine. - Hepatic impairment: use with caution; monitor liver enzymes. - Electrolyte imbalance: check potassium levels regularly. - Pregnancy: contraindicated in the second and third trimesters. - Concomitant diuretics: monitor blood pressure and electrolytes closely. Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Panoprist may interact with several drug classes; careful review is required.

Major Interactions (Avoid): - Aliskiren: risk of additive renal dysfunction and hyperkalaemia. - Potassium‑rich supplements: increase hyperkalaemia risk. - NSAIDs: may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Diuretics (loop/thiazide): may enhance hypotensive response. - Lithium: increased lithium levels and toxicity risk. - Antidiabetic drugs: may require dose adjustment of glucose‑lowering agents.